MindWalk Holdings (HYFT) Asset Utilization Ratio (2021 - 2026)
MindWalk Holdings (HYFT) posted quarterly Asset Utilization Ratio of 371.93 for Q2 2026, up 75.3% year-over-year from 212.17 in Q2 2025, and down 16.55% quarter-over-quarter from 445.67 in Q1 2026.
MindWalk Holdings (HYFT) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Asset Utilization Ratio for 6 consecutive years, with 371.93 the latest figure, recorded in Q2 2026.
- In Q2 2026, Asset Utilization Ratio rose 75.3% year-over-year to 371.93; the TTM figure through Apr 2026 stood at 371.93 (up 75.3% YoY), while the FY2026 annual figure was 0.48, up 139.17% from the prior year.
- Asset Utilization Ratio declined to 371.93 in Q2 2026 per HYFT's latest filing, from 445.67 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 445.67 in Q1 2026 and bottomed at 0.08 in Q1 2022.
- Historically, Asset Utilization Ratio has averaged 91.6 across 5 years, with a median of 0.3 in 2024.
- Annual changes were most pronounced in 2024 — Asset Utilization Ratio sank 42.91% — and 2025, when it soared 141764.74%.
- MindWalk Holdings' Asset Utilization Ratio stood at 0.25 in 2022, then advanced by 19.21% to 0.3 in 2023, then surged by 13864.07% to 41.43 in 2024, then soared by 684.99% to 325.25 in 2025, then rose by 14.35% to 371.93 in 2026.
- Business Quant data shows HYFT's Asset Utilization Ratio at 371.93 in Q2 2026, 445.67 in Q1 2026, and 325.25 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 371.93 |
| Jan 31, 2026 | 445.67 |
| Oct 31, 2025 | 325.25 |
| Jul 31, 2025 | 161.35 |
| Apr 30, 2025 | 212.17 |
| Jan 31, 2025 | 47.49 |
| Oct 31, 2024 | 41.43 |
| Jul 31, 2024 | 41.34 |
| Apr 30, 2024 | 0.15 |
| Jan 31, 2024 | 0.31 |
| Oct 31, 2023 | 0.30 |
| Jul 31, 2023 | 0.28 |
| Apr 30, 2023 | 0.26 |
| Jan 31, 2023 | 0.25 |
| Oct 31, 2022 | 0.25 |
| Jul 31, 2022 | 0.17 |
| Apr 30, 2022 | 0.13 |
| Jan 31, 2022 | 0.08 |
| Oct 31, 2021 | 0.07 |
| Jul 31, 2021 | 0.13 |